Better risk stratification can improve clinical decision making and better outcomes, experts involved in the study explained in EJR.

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

A clinical trial pitting MRI against a burgeoning PET/CT technique has found the de facto defending champion better at revealing the presence of any grade of prostate cancer.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

"Clinical study protocols may involve more than one PET [amyloid-beta] scan per patient,” the CMS announcement said.

PET/CT imaging in these patients increases overall survival depending on the cancer’s stage, with those diagnosed with stage 3A and 3B NSCLC appearing to benefit the most from the exam. 

This week in AJR, experts shared how they were able to reduce FDG PET scan acquisition times by 33%, thus reducing the amount of total radiation exposure to more vulnerable pediatric patients. 

Alexander Ding, MD, a radiologist and incoming American Medical Association (AMA) Board of Trustees member, explains the new AMA policy calling on Congress to change the language and implementation of the current Medicare mandate that all advanced medical imaging needs certification.